alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 301–325 of 1,426 studies scoring ≤ 29 out of 100 (page 13 of 58) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Evaluation of Reminiscence Therapy on Language Outcomes Among People With Dementia

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Perspectives of the ASHA Special Interest Groups 2025-07-25

There was a significant correlation in MoCA and FLCI-2 measures but no significant correlation between the language measures (CIUs, FLCI-2, or word count). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ENHANCED ALZHEIMER DISEASE DIAGNOSIS THROUGH DEEP LEARNING-BASED MRI SEGMENTATION AND CLASSIFICATION

✓ Peer-reviewed alzhub usefulness score 26 out of 100. RCHUB JOURNAL OF COMPUTATIONAL INTELLIGENCE SCIENCE AND ENGINEERING (JCISE) 2026-07-01

The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cuando el Alzheimer llega antes de lo esperado: la mutación del gen PSEN1

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Con Evidencia 2025-01-01

Studies in Jalisco have identified a mutation in the PSEN1 gene, associated with early-onset Alzheimer's. This variant, common in the Altos de Jalisco region, affects both men and women, causing severe symptoms such as difficulty walking and speaking. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ALZHEIMER PRECOCE: FATORES PREDISPONENTES, DIAGNÓSTICO E MANEJO

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Revista Ibero-Americana de Humanidades, Ciências e Educação 2026-05-12

Esse artigo buscou abordar a Doença de Alzheimer de Início Precoce (DAIP) acerca do curso clínico, dos fatores predisponentes e do manejo, por meio de uma revisão de literatura, com ênfase na diferenciação entre DAIP e Doença de Alzheimer de Início Tardio (DAIT), incluindo artigos publicados entre 2015 e 2025, obtidos nas bases de dados “Alzheimer's Association”, “ScienceDirect”, “Cochrane” e “PubMed”, utilizando as palavras-chave “Alzheimer”, “early” e “on-set”, com o conectivo AND. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Etomidate ameliorates Alzheimer-like neuropathology and cognitive impairment in APP/PS1 mice

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2025-02-01

To investigate the effect and mechanism of etomidate on attenuating Alzheimer-like neuropathology and cognitive impairment in mice with Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Más allá del realismo y el constructivismo: el Alzheimer como resfactum en una ontología relacional de las entidades biomédicas

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Discusiones Filosóficas 2025-07-01

Este artículo cuestiona la dicotomía entre realismo y constructivismo en la filosofía de la ciencia, argumentando que resulta insuficiente para comprender entidades biomédicas como el Alzheimer. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multifunctional Tannins from Phyllanthus amarus Exhibit Disease-Modifying Activities Against Alzheimer's Pathogenesis: An In Vitro and In Vivo Investigation

✓ Peer-reviewed alzhub usefulness score 26 out of 100. IJPAR JOURNAL 2026-02-13

Alzheimer's disease (AD) manifests as a chronic neurodegenerative syndrome featuring cognitive impairment alongside characteristic neuropathological markers: amyloid-beta (Aβ) plaques and tau-associated neurofibrillary tangles. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

BIOMARCADORES PLASMÁTICOS NA DETECÇÃO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO SISTEMÁTICA

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Cognitus Interdisciplinary Journal 2025-05-20

A Doença de Alzheimer (DA) é uma enfermidade neurodegenerativa progressiva cuja detecção precoce é essencial para intervenções terapêuticas eficazes. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Validity and Reliability of a Chinese-Tailored Scale for the Evaluation of End-of-Life Care in Dementia Patients

✓ Peer-reviewed alzhub usefulness score 26 out of 100. British Journal of Hospital Medicine 2025-07-22

In this study, a preliminary reliability assessment on the Chinese version of the EOLD scale was conducted, revealing that the three subscales exhibit strong internal consistency in reliability and structural validity. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Stakeholder Perspectives on Integrating ADEPT Into End‐Of‐Life Care for Nursing Home Residents With Dementia: A Qualitative Descriptive Study

✓ Peer-reviewed alzhub usefulness score 26 out of 100. International Journal of Older People Nursing 2026-05-01

Current processes for identifying hospice-eligible residents rely on regular assessments and interdisciplinary collaboration but reveal significant gaps, including delays in referrals and inconsistent practices. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy

✓ Peer-reviewed alzhub usefulness score 26 out of 100. The journal of prevention of Alzheimer's disease 2026-08-13

Amyloid immunotherapy with lecanemab and donanemab has been approved on the basis of statistically significant slowing of cognitive and functional decline in early Alzheimer's disease (1,2). 2 key findings →

Design: post-hoc analysis Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed